Riociguat Gastric Retention Extended-Release Capsules (Triastek)

利奥西呱胃滞留缓释胶囊 (南京三迭纪医药 )

Report date: 2025/06/13 17:49:58

Base Information

Drug NameRiociguat Gastric Retention Extended-Release Capsules (Triastek)
Drug Alias Name利奥西呱胃滞留缓释胶囊（2.2改良型）T-22
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSoluble guanylate cyclase stimulants
TargetsSoluble guanylate cyclase
Therapy Area/IndicationsChronic thromboembolic pulmonary hypertensionPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Triastek Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Triastek Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic thromboembolic pulmonary hypertensionPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A